These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 38530500)
1. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500 [TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044 [TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study. Yoon H; Ye BD; Kang SB; Lee KM; Choi CH; Jo JY; Woo J; Cheon JH BMC Gastroenterol; 2024 Aug; 24(1):273. PubMed ID: 39160459 [TBL] [Abstract][Full Text] [Related]
5. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488 [TBL] [Abstract][Full Text] [Related]
6. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234 [TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ; Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087 [TBL] [Abstract][Full Text] [Related]
8. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis. Lopes SR; Martins C; Teixeira M; Tomás D World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781 [TBL] [Abstract][Full Text] [Related]
9. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA; J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965 [TBL] [Abstract][Full Text] [Related]
10. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214 [TBL] [Abstract][Full Text] [Related]
11. Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib. van Gennep S; Fung ICN; Jong DC; Ramkisoen RK; Clasquin E; de Jong J; de Vries LCS; de Jonge WJ; Gecse KB; Löwenberg M; Woolcott JC; Mookhoek A; D'Haens GR J Crohns Colitis; 2024 Aug; 18(8):1283-1291. PubMed ID: 38506097 [TBL] [Abstract][Full Text] [Related]
12. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585 [TBL] [Abstract][Full Text] [Related]
13. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience. Parra-Izquierdo V; Frías-Ordoñez JS; Cuadros C; Vargas M; Vera Chamorro JF; Romero Sanchez C; Flórez-Sarmiento C Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832 [TBL] [Abstract][Full Text] [Related]
14. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon. Sharara AI; Alrazim A; Saniour P; Daniel F; Rached AA; Bahr A; Azar C; Geagea A; Ghoubar M BMC Gastroenterol; 2024 Oct; 24(1):349. PubMed ID: 39367371 [TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. Kotwani P; Terdiman J; Lewin S J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189 [TBL] [Abstract][Full Text] [Related]
16. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T; Bacsur P; Keresztes C; Bálint A; Bor R; Fábián A; Farkas B; Katsanos K; Michalopoylos G; Ribaldone DG; Attauabi M; Zhao M; Barak HA; Yanai H; Bezzio C; Rispo A; Castiglione F; Bar-Gil Shitrit A; Pugliese D; Armuzzi A; Savarino EV; Kolar M; Lukáš M; Chashkova E; Filip R; Rozieres A; Nancey S; Krznarić Ž; Schäfer E; Szamosi T; Sarlós P; Franko M; Drobne D; Knyazev OV; Kagramanova AV; Limdi J; Wetwittayakhlang P; Lakatos PL; Maharshak N; Bannon L; Nyári T; Szepes Z; Farkas K; ; Molnár T Inflamm Bowel Dis; 2024 May; 30(5):768-779. PubMed ID: 37542737 [TBL] [Abstract][Full Text] [Related]
17. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M; Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343 [TBL] [Abstract][Full Text] [Related]
18. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study. Ollech JE; Eran-Banai H; Goren I; Sharar Fischler T; Avni-Biron I; Snir Y; Broitman Y; Cohen S; Friedenberg A; Pauker MH; Dotan I; Yanai H Ann Med; 2024 Dec; 56(1):2358183. PubMed ID: 38813808 [TBL] [Abstract][Full Text] [Related]
19. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Uzzan M; Bresteau C; Laharie D; Stefanescu C; Bellanger C; Carbonnel F; Serrero M; Viennot S; Nachury M; Amiot A; Altwegg R; Picon L; Nahon S; Vuitton L; Ah Soune P; Kirchgesner J; Peyrin-Biroulet L; Bouhnik Y; Aliment Pharmacol Ther; 2021 Aug; 54(3):312-319. PubMed ID: 34151448 [TBL] [Abstract][Full Text] [Related]
20. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study. Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]